ZIOPHARM Oncology Inc (ZIOP) : Zacks Investment Research ranks ZIOPHARM Oncology Inc (ZIOP) as 2, which is a Buy recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 2.6, which indicates as a Hold.
ZIOPHARM Oncology Inc (ZIOP) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $21 and the lowest price target forecast is $7. The average forecast of all the analysts is $14 and the expected standard deviation is $9.9.
Company shares have received an average consensus rating of Hold for the current week ZIOPHARM Oncology Inc (NASDAQ:ZIOP): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.15 and $5.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.27. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.21, notching a gain of 1.36% for the day. The total traded volume was 1,730,361 . The stock had closed at $5.14 on the previous day.
In a related news, Belbel Caesar J, officer (COO, CLO, and Secretary) of Ziopharm Oncology Inc, unloaded 153,333 shares at an average price of $12.84 on November 19, 2015. The total amount of the transaction was worth $1,968,796, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).